Cannabinoid system is a potential target for pain control. Cannabinoid receptor 1 (CB 1 ) activation play a role in the analgesic effect of cannabinoids once it is expressed in primary afferent neurons. This study investigates whether the anti-hyperalgesic effect of CB 1 receptor activation involves P2X 3 receptor in primary afferent neurons. Mechanical hyperalgesia was evaluated by electronic von Frey test. Cannabinoid effect was evaluated using anandamide or ACEA, a non-selective or a selective CB 1 receptor agonists, respectively; AM251, a CB 1 receptor antagonist, and antisense ODN for CB 1 receptor. Calcium imaging assay was performed to evaluated α,β-meATP-responsive cultured DRG neurons pretreated with ACEA. Anandamide or ACEA administered in peripheral tissue reduced the carrageenan-induced mechanical hyperalgesia. The reduction in the carrageenaninduced hyperalgesia induced by ACEA was completely reversed by administration of AM251 as well as by the intrathecal treatment with antisense ODN for CB 1 receptor. Also, ACEA reduced the mechanical hyperalgesia induced by bradykinin and by α,β-meATP, a P2X 3 receptor non-selective agonist, but not by tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β) and chemokine-induced chemoattractant-1 (CINC-1). Finally, CB 1 receptors are co-localized with P2X 3 receptors in DRG small-diameter neurons and the treatment with ACEA reduced the number of α,β-meATP-responsive cultured DRG neurons. Our data suggest that the analgesic effect of CB 1 receptor activation is mediated by a negative modulation of the P2X 3 receptor in the primary afferent neurons.
Introduction
The importance of cannabinoid system and its potential therapeutic effect on pain management increased considerably in the last few years. Cannabinoid action is mediated by two receptors, CB 1 and CB 2 , both coupled to inhibitory Gi/o proteins (Ahluwalia et al., 2000; Freund and Hajos, 2003; Hohmann and Herkenham, 1999; Piomelli, 2005) . Cannabinoid CB 1 receptors are expressed in central nervous system (CNS) (Matsuda et al., 1990; Munro et al., 1993; Zimmer et al., 1999) , and in peripheral nervous system specifically in the nociceptive afferent fibers of the dorsal root ganglion (DRG) (Ahluwalia et al., 2000; Hohmann and Herkenham, 1999; Veress et al., 2013) , cutaneous tissue (Agarwal et al., 2007; Amaya et al., 2006; Stander et al., 2005) , keratinocytes and immune cells (Gaffal et al., 2013; JeanGilles et al., 2015; Mai et al., 2015) . Cannabinoid CB 2 receptors, in turn, occur in CNS and non-neuronal cells of the peripheral tissue, particularly immune cells (Agarwal et al., 2007; Amaya et al., 2006; Pertwee, 2006) .
Cannabinoid receptors activation in the peripheral tissue prevents signs of tonic pain induced by administration of inflammatory agent in animals (Gutierrez et al., 2007; Pertwee, 2006) . Thus, activation of cannabinoid receptors by anandamide, a non-selective cannabinoid receptor agonist, or ACEA, a selective CB 1 receptor agonist, reduces carrageenan-induced inflammatory hyperalgesia in the rat hind paw (Clayton et al., 2002; Gutierrez et al., 2007; Nackley et al., 2003) . Mechanical hyperalgesia induced by carrageenan is a model of inflammatory pain widely used since it is sensitive to non-steroidal anti-inflammatory drugs similarly to many inflammatory conditions in humans (Ferreira et al., 1993a) . Administration of carrageenan in the subcutaneous tissue of rat hind paw leads to the release of bradykinin and subsequent release of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), interleukin-1beta (IL-1β), interleukin-6 (IL-6) and interleukin-8 (IL-8) (Ferreira et al., 1993b (Ferreira et al., , 1974 . These cytokines induce the release of prostaglandins and sympathetic amines, which are final inflammatory mediators that ultimately will sensitize the nociceptors (Gold et al., 1996; Rush and Waxman, 2004) .
Moreover, a previous study showed that during carrageenaninduced inflammation the bradykinin triggers ATP release and consequent neuronal P2X 3 receptor activation (Oliveira et al., 2009 ). This activation contributes to the susceptibility of the nociceptor to the action of inflammatory mediators facilitating the development of inflammatory hyperalgesia (Prado et al., 2013) . It has been suggested that activation of cannabinoid CB 1 receptor negatively modulates P2X receptor activity in vitro (Krishtal et al., 2006) . Considering this interaction among CB 1 and P2X receptors, it is plausible to hypothesize that the anti-hyperalgesic effect of CB 1 receptor activation may be mediated by the decreasing of P2X 3 receptor activity. Thus, this study aimed to investigate whether the mechanism by which the activation of peripheral cannabinoid CB 1 receptor reduces the carrageenan-induced mechanical hyperalgesia involves the modulation of P2X 3 receptor.
Materials and methods

Animals
Experiments were performed using 233 adult male Wistar rats (150-200 g) in agreement with the guidelines of the IASP on laboratory animal care (Zimmermann, 1983) . All animal protocols and experimental procedures followed the guidelines of the Ethics Committee for Animal Research, State University of Campinas, and were approved by the Committee for Multidisciplinary Research in Biological Science Area of Laboratory Animals (CEMIB, protocol number: 2799-1).
The animals (specific pathogen free -SPF) were housed in plastic cages with soft bedding (five/cage) on a 12:12 light cycle, with food (commercial chow for rodents) and filtered water available ad libitum, in a temperature-controlled room ( ± 23°C). Testing sessions took place during the light phase (09:00 AM-5:00 PM) in a quiet room maintained at 23°C. During the tests, the animals had no access to water or food. All efforts were made to minimize both the stress of rats and the number of animals per group. The group size (n) for each experimental group is showed in "Results sections". Animals were divided randomly into the groups. The experimenter blinded to the experimental groups made all analyses.
Drugs and doses
λ-carrageenan (100 μg/paw , Sigma-Aldrich, MO, USA); bradykinin (500 ng/paw (Cunha et al., 2000) , SigmaAldrich, MO, USA); α,β-methyleneATP lithium salt (α,β-meATP), a non-selective P2X 3 receptor agonist (50 μg/paw (Prado et al., 2013) , Sigma-Aldrich, MO, USA), were all dissolved in saline (0.9% NaCl). ACEA, a selective cannabinoid CB 1 receptor agonist (N-2-Chloroethil)−5Z,8Z,11Z,14Z-eicosatetraenamida] (0.1, 1.0 and 10 μg/ paw (Sagar et al., 2005) , Tocris Bioscience, Bristol, UK) was diluted in ethanol and saline. Anandamide, a non-selective cannabinoid receptor agonist, was dissolved in Tocrisolve TM 100 [N-2-Hydroxyethil)−5Z,8Z,11Z,14Z-eicosatetraenamide] (0.03, 0.1, 0.3 and 0.9 ng/paw (Schreiber et al., 2012) , Tocris Bioscience, Bristol, UK). AM251, a selective cannabinoid CB 1 receptor antagonist (80 μg/paw (Richardson et al., 1998) , Tocris Bioscience, Bristol, UK) was dissolved in 10% propyleneglycol. Tumor necrosis factor alpha (TNF-α, 2.5 pg/ paw; Cunha et al., 2008) , Interleukin 1 beta (IL-1β, 0.5 pg/paw; Araldi et al., 2013; Cunha et al., 2008) , chemokine-induced chemoattractant-1 (CINC-1, 100 pg/paw, Cunha et al., 2008) were bought from National Institute of Biological Standards and Control, South Mimms, Hertfordshire, UK. α,β-meATP was dissolved in Hanks buffer for primary DRG cultures (30 μM) (Grubb and Evans, 1999) .
Subcutaneous injection
Animals were quickly restrained and the drugs or vehicle (50 µl) was subcutaneously injected in the rat intraplantar tissue of the hind paw (Vivancos et al., 2003) . A BD Ultra-Fine® needle (30 gauge) with a insulin syringe (30 units) was used to the intraplantar injection.
Intrathecal injection
Based on Papir-Kricheli (Papir-Kricheli et al., 1987) , antisense ODN was administered into the subarachnoid space. Rats were briefly anesthetized with 5% halothane (Le Bars et al., 1979) , a needle (29 gauge) was inserted in the midline between the lumbar vertebrae (L4 and L5), and antisense ODN was injected at 1 µl/s. Antisense ODN against CB 1 receptor (30 µg/10 µl) was intrathecally administered once a day over 4 days (Barclay et al., 2002) . Behavioral test was performed following the last day of antisense ODN injection.
Evaluation of the hyperalgesia
Hyperalgesia was measured by electronic pressure-meter paw test for rats. Before testing, rats were placed in acrylic cages (12×20×17 cm) with a wire grid floor during 15-30 min and the paws were tested 2-3 times for adaptation. For the test, a hand-held force transducer with a 0.5 mm 2 polypropylene tip (electronic von Frey, TC Inc. Life Science Instruments, USA) was used to induce a paw flexion reflex (Vivancos et al., 2004) . A clear view of the rat hind paw was provided by a tilted mirror under the grid floor. The investigator was instructed to handle the tip applying a progressive increasing force, not exceeding 80 g, in the rat hind paw. The tip was applied between the five distal footpads. The mechanical stimulus was repeated from three to six times up to the animal presented three similar measurements. A typical flinch response following the hind paw withdrawal determined the end point. The animals that did not respond consistently were removed from the experimental group. The pressure applied to the hind paw was measured (in grams) and automatically recorded when the paw was withdrawn. The intensity of hyperalgesia was presented as Δ withdraw threshold, obtained by subtracting values measured before the treatment from those obtained after the treatment.
Antisense Oligodeoxynucleotide (AS-ODN)
The intrathecal treatment with antisense ODN was performed to block the CB 1 receptor function only in the nociceptor (Prado et al., 2013; Yu et al., 2009 ). The antisense ODN sequence against CB 1 receptor transcript was: 5′-TGAATCATGCGGACCGCGT-3′. The mismatch ODN sequence with six bases changed was: 5′-TTACTCAG GCTGGCCGAGT-3′. Agreeing to NCBI database to Rattus norvegicus there are no other homologous sequences. The ODNs were purchased lyophilized from Exxtend (Campinas, SP, Brazil), reconstituted in saline, aliquoted and stored at −20°C for using during the treatment.
Analysis of CB 1 expression by western blotting
The analysis of cannabinoid CB 1 receptor expression was performed to verify the efficacy of intrathecal antisense ODN treatment against this protein. L4 and L5 DGR were harvested, frozen in liquid nitrogen and stored at −80°C for using in the immunoblotting. To the immunoblotting, DRG samples were homogenized with an ultrasonic homogenizer (Sonic Corporation, USA) in a buffer solution with 1% Triton X-100, 50 mM phosphate buffer pH 7.4, 8 M urea, 2 M thiourea, 1 mM EDTA, 1% protease inhibitor mix complete (P8340, Sigma, USA) and then incubated for 20 min at 4°C. After, the samples were centrifuged at 12000g for 15 min at 4°C and the supernatant was taken. The concentration of total protein was determined by the Bradford method, and 70 µg of total proteins of each sample were separated by SDS-PAGE. The proteins were transferred to nitrocellulose membrane agreeing to standard techniques. Membranes were stained with Ponceau S USB™ and the total protein was quantified using a image system (GeneTools Software, Syngene, Cambridge, UK).
Membranes were prepared using 5% non-fat dry milk solution in PBS containing 0.1% tween-20. After, it was incubated overnight with a goat polyclonal CB 1 receptor antibody (1:1000; SAB2500190; SigmaAldrich, MO, USA), and subsequently, with a rabbit anti-goat HRP conjugated secondary antibody (1:10000; 81620; Zymed − Life Technologies; CA, USA) for 1 h. Immunoreactive bands were detected by using chemiluminescence kit SuperSignal West Pico (Life Technologies; CA, USA), and their optical densities were quantified by a computer program (GeneTools Software, Syngene, Cambridge, UK). The relative optical density was calculated between the optical density (OD) of immunoreactive CB 1 receptor band and the OD of total protein band stained with Ponceau for each sample. This procedure enabled to use OD of total protein bands as an internal control (Ignarro et al., 2013; Romero-Calvo et al., 2010) .
Enzyme-linked immunosorbent assay (ELISA) procedure
An adaptation of ELISA (Safieh-Garabedian et al., 1995) was used to determine whether ACEA was able to reduce the carrageenaninduced increased concentration of TNF-α, IL-1β and CINC-1. The subcutaneous tissue of the dorsum of the rat hind paw was collected 180 min post the subcutaneous injection of carrageenan or its vehicle (NaCl 0.9%). These tissues were weighed and homogenized in the same weigh/volume proportion in a solution of phosphate-buffered saline (PBS) containing 0.4 M NaCl, 0.05% Tween 20, 0.5% bovine serum albumine (BSA), 0.1 mM phenyl-methyl-sulfonyl fluoride, 0.1 mM benzotonic chloride, 10 mM EDTA, and 20 kL/ml aprotinine (Sigma, USA, Sigma-Aldrich, MO, USA). The supernatants were stored at -70°C until further analysis. The levels of TNF-α, IL-1β and CINC-1 were evaluated using sandwich ELISA. ELISA kits for TNF-α, IL-1β and CINC-1 were from the National Institute for Biological Standards and Control (Potters Bar, UK). Briefly, sheep polyclonal anti-rat TNF-α IgG-raised TNF-α (2.0 µg/ml), sheep polyclonal anti-rat IL-1β, IgGraised IL-1β (2.0 µg/ml) or sheep polyclonal anti-rat CINC-1, IgGraised CINC-1/CXCL1 (3.0 µg/ml) diluted in 50 µl PBS buffer, was used to coat microtiter plates (Nunc Maxisorb, Roskilde, Denmark). Blocking of nonspecific binding sites was accomplished by incubating plates with PBS containing 2% BSA for 90 min at 37°C. After incubation (4°C, overnight) and washing the plates in assay buffer (0.01 M phosphate, 0.05 M NaCl, 0.1% Tween 20, pH 7.2), 50 µl standard (TNF-α, IL-1β, CINC-1 or sample) was added to each well and incubated overnight at 4°C. After washing the plates, 50 µl biotinylated rabbit polyclonal anti-rat TNF-α (1:2000 with assay buffer plus 1% normal sheep serum) and rabbit anti-rat IL-1β (1:2000) or sheep polyclonal anti-rat CINC-1 IgG (diluted 1:500) antibody for 30 min at 37°C were added to the plates and incubated for 1 h at room temperature. After incubation, the plates were washed again, and 50 µl avidin-peroxidase conjugate (1:5000 dilution, Dako, Carpinteria, CA, USA) was added to all the wells, and the wells were incubated for 30 min with 50 µl substrate (40 µg/well, orthophenylenediamine dihydrocloride, Sigma-Aldrich, MO, USA). After color development, the reaction was stopped with the addition of sulfuric acid (1 M). Absorbance was measured at 490 nm. These ELISA methods consistently detected TNF-α, IL-1β and levels over 20 pg/ml and did not cross-react with other cytokines. The results are expressed as picograms (pg) of each cytokine per paw. As a control, the concentrations of these cytokines were determined in naïve rats and in animals injected with saline.
Primary Dorsal Root Ganglia (DRG) culture
After euthanizing under anesthesia, rat DRGs were harvested agreeing to the methodology previously described (Linhart et al., 2003) . Cells were dissociated from tissue and plated in six-well plastic plates coated with Matrigel (BD). The cultures were maintained in a humid 5% CO 2 atmosphere at 37°C for 24-36 h.
Intracellular calcium dynamics of cultured DRG neurons
Cultured DRG cells were incubated with Hanks solution (5 μM of Fluo4-AM; Invitrogen, NY, USA) and 1% Powerload (Invitrogen) for 30 min. Then, cultured cells were placed in a perfusion chamber (Warner Instruments, CT, USA) adapted in a fluorescent microscope (Leica DMI6000, Leica, Germany) with epifluorescence (excitation 480 nm, suppression 527/30 nm) and with a coupled digital camera for image capture (1 image/sec). An 8-dispersion valve system was used to control the flux (3 ml/min) through the chamber (Warner Instruments, CT, USA), promoting complete perfusion change within the chamber every 3 s.
Cultured cells were initially incubated during 300 s with either Hanks (5 mM K+) or ACEA (Tocris Bioscience, Bristol, UK). Then, the culture plate was perfused with αβ-met-ATP (Sigma, MO, USA) for 20 s and washed with Hanks (5 mM K + ) for 60 s. All plates were perfused with Hanks (50 mM K + ) after the end of the assay and only the 50 mM potassium-responsive cells were considered for analysis.
DRG Immunohistochemistry
After deep anesthesia with co-injection of ketamine (i.p. 85 mg/ kg)/xylazine (i.p. 10 mg/kg) rats were perfused with saline (0.9% NaCl) followed by 4% paraformaldehyde (PFA, pH 7.4, 4°C) through the ascending aorta. After, DRGs were harvest, fixed in 4% PFA for 24 h and put in 30% sucrose solution for 48 h. Each DRG were embedded in optimum cutting temperature and cut into 12 µm sections using a cryostat. These sections were put on gelatinized slides and stored at −20°C. Before the immunofluorescence procedure, slides were dried overnight, and it was performed the heat induced epitope retrieval with citrate buffer (10 mM Sodium Citrate, 0.05% Tween 20, pH 6.0 at 75°C for 30 min). After cooling for 30 min at room temperature, tissue sections were blocked with 2% BSA in 0.1% Triton X-100 for 1 h. A goat polyclonal CB 1 receptor antibody (1:500, SAB2500190; SigmaAldrich, MO, USA) and a rabbit polyclonal P2X 3 antibody (1:1000, AB5896, Merck Millipore, Billerica, MA, USA) were diluted in 0.05% Triton X-100 in 0.1 M PBS and incubated with the DRG tissues overnight (4°C) in a humid atmosphere. Anti-goat (Alexa 594) and anti-rabbit (Alexa 488) conjugated secondary antibodies (1:500) were incubated with DRG tissue for 2 h at room temperature, and nuclei were stained using DAPI (0.25 μg/ml; Sigma D9542) for 10 min. Sections were analyzed using a fluorescence microscope (Leica, DMI 6000B, Leica Microsystems, Germany).
Statistical analysis
The statistical analysis was carried out using GraphPad Prism version 4 (GraphPad Software, San Diego, CA). Results were presented as mean ± S.E.M. of six rats for each group. One-way analysis of variance (ANOVA) with treatment factor was used to calculate the degree of significance among groups, followed by the Tukey's multiple comparison test to compare the groups. Unpaired t-test was used when two groups were compared.
Results
Activation of peripheral cannabinoid CB 1 receptor decreases the carrageenan-induced mechanical hyperalgesia
Local administration of carrageenan (100 µg/paw) in the subcutaneous tissue of rat hind paw induced mechanical hyperalgesia evaluated 3 h after its injection. Anandamide, a non-selective cannabinoid receptor agonist (0.03, 0.1, 0.3 and 0.9 ng/paw) or ACEA, a selective cannabinoid CB 1 receptor agonist (0.1, 1 and 10 µg/paw) was administered at the same site 2.5 h after carrageenan. As shown in Fig. 1 , anandamide and ACEA decreased the mechanical hyperalgesia (1A and 1B, respectively; One-way ANOVA followed by Tukey's test; F 5,30 =111.0 and F 5,30 =62.51, respectively; P < 0.05, n=6 per group). To demonstrate the participation of CB 1 receptor activation in anandamide-induced anti-hyperalgesic effect and to confirm the selective effect of ACEA (1 µg/paw) on carrageenan-induced hyperalgesia, the selective cannabinoid CB 1 receptor antagonist AM251 (80 µg/paw) was administered 30 min before anandamide or ACEA. AM251 reduced the anti-hyperalgesic effect induced by anandamide or ACEA (1C and 1D, respectively; One-way ANOVA followed by Tukey's test; F 4,25 =72.04 and F 4,25 =119.6, respectively; P < 0.05, n=6 per group). To rule out the systemic effect ACEA (1 µg/paw) was administered in the contralateral hind paw and did not induce a change in the mechanical withdrawal threshold. The following experiments were performed using this dose.
Activation of cannabinoid CB 1 receptor reduces the bradykinininduced mechanical hyperalgesia but not affect the pro-inflammatory cytokines-induced hyperalgesia
Since activation of CB 1 receptor reduced the carrageenan-induced hyperalgesia, its effect on the hyperalgesia induced by bradykinin and pro-inflammatory cytokines was evaluated. Local administration of bradykinin, TNF-α, IL-1β, CINC-1 in the subcutaneous tissue of rat hind paw produced mechanical hyperalgesia evaluated 3 h after its injection. ACEA (1 µg/paw) was administered at the same site 2.5 h after bradykinin, TNF-α, IL-1β, CINC-1. As shown in Fig. 2A , ACEA (1 µg/paw) reduced the mechanical hyperalgesia induced by bradykinin (500 ng/paw) (Unpaired t-test; P < 0.05, n=6 per group), but did not alter the mechanical hyperalgesia induced by TNF-α (2.5 pg/paw), IL-1β (0.5 pg/paw) and CINC-1 (100 pg/paw) (Unpaired t-test; P > 0.05, n=6 per group).
To verify whether the anti-hyperalgesic effect of CB 1 receptor activation could be mediated by the decreasing of the release of proinflammatory cytokines, TNF-α, IL-1β and CINC-1 concentration were evaluated in the carrageenan-induced hyperalgesia in the rat hind paw. Fig. 1 . Activation of peripheral cannabinoid CB 1 receptor reduces the carrageenan-induced mechanical hyperalgesia. Anandamide (0.3 and 0.9 ng/paw) or ACEA (0.1, 1 and 10 µg/ paw) administered in the hind paw 2.5 h after carrageenan inhibited the mechanical hyperalgesia evaluated 30 min later (A and B, respectively). This effect was significantly reversed by administration of the selective cannabinoid CB 1 receptor antagonist AM251 (80 µg/paw) 30 min before anandamide or ACEA (C and D, respectively). ACEA 1 μg/paw, administered in contralateral paw (Ct) did not change the mechanical withdrawal threshold. The symbols ''*", ''#", and "∞" mean statistically different from other groups (One-way ANOVA, Tukey's test; P < 0.05). Sal: saline.
As shown in Fig. 2 , local administration of carrageenan (100 µg/paw) in subcutaneous tissue of the hind paw increases concentration of TNF-α, IL-1β and CINC-1, measured 3 h after its injection. ACEA (1 µg/ paw) administered at the same site 2.5 h after carrageenan did not affect the increased concentration of TNF-α (2B), IL-1β (2 C) and CINC-1 (2D) induced by carrageenan (One-way ANOVA, Tukey's test; F 2,12 =18.85, F 2,12 =19.23 and F 2,12 =11.52, respectively; P > 0.05).
3.3. The anti-hyperalgesic effect of ACEA is decreased by intrathecal administration of antisense ODN against cannabinoid CB 1 receptor in the peripheral tissue Once the anti-hyperalgesic effect of CB 1 receptor activation does not involve the release of cytokines, we verified whether CB 1 receptors expressed on the primary afferent neurons mediates the anti-hyperalgesic effect of ACEA. Thus, antisense ODN against CB 1 receptor was intrathecally administered. Local administration of ACEA (1 μg/paw) in the subcutaneous tissue decreased the carrageenan-induced mechanical hyperalgesia and, in turn, antisense ODN (30 μg/10 µl once a day, for 4 days), but not its mismatch ( Fig. 3A ; One-way ANOVA followed by Tukey's test; F 3,20 =58.83; P < 0.05, n=6 per group), prevented the anti-hyperalgesic effect of ACEA. Fig. 3B shows that the expression of CB 1 receptor in the DRG was reduced by intrathecal administration of the antisense ODN (Unpaired t-test; P < 0.05).
3.4. Activation of cannabinoid CB 1 receptor reduces α,β-meATPinduced hyperalgesia in rat hind paw and decreases the responsiveness of DRG small-diameter neurons to the α,β-meATP Since CB 1 receptor activation reduced the hyperalgesia induced by bradykinin which triggers ATP release, the next step was to verify whether this anti-hyperalgesic effect is related to P2X 3 receptor. Local administration of α,β-meATP (50 ng/paw) in the subcutaneous tissue of rat hind paw produced mechanical hyperalgesia evaluated 3 h after its injection. ACEA (1 µg/paw) was administered at the same site 2.5 h after α,β-meATP. As shown in Fig. 4A , ACEA (1 µg/paw) significantly reduced the α,β-meATP-induced mechanical hyperalgesia (Unpaired ttest; P < 0.05, n=6 per group). To verify the interaction between CB 1 and P2X 3 receptors, it was analyzed the effect of ACEA on the calcium influx induced by α,β-meATP in cultured DRG neurons and the coexpression of CB 1 and P2X 3 receptors in DRG small-diameter neurons. Administration of α,β-meATP (30 µM) induced a rise in intracellular calcium levels of the cultured DRG small-diameter neurons. As shown in Fig. 4B , pre-treatment with ACEA (3 µM) reduced the responsiveness of approximately 96% cultured DRG small-diameter neurons to the α,β-meATP (Unpaired t-test; P < 0.05, n=6 per group). Figs. 4C and 4D are representative of the response of the cell pre-treated with ACEA or its vehicle to the α,β-meATP administration. Fig. 4E demonstrates that DRG small-diameter neurons may co-express P2X 3 and CB 1 receptors.
Discussion
This study showed that the activation of peripheral cannabinoid receptors by anandamide, a non-selective cannabinoid receptor agonist, reduces the carrageenan-induced mechanical hyperalgesia confirming previous findings (Clayton et al., 2002) . Moreover, we demonstrated that the selective CB 1 receptor antagonist, AM251, reduces the anti-hyperalgesic effect of anandamide evidencing that the activation of the CB 1 receptor in the peripheral tissue impairs the inflammatory hyperalgesia. Indeed, administration of the selective CB 1 receptor agonist, ACEA, in the hind paw decreased the carrageenan-induced hyperalgesia, and this effect was entirely prevented by administration of AM251, a selective CB 1 receptor antagonist. These data are in Fig. 2 . Activation of cannabinoid CB1 receptor reduces bradykinin-induced hyperalgesia and does not change the release of pro-inflammatory cytokines induced by carrageenan. (A) Local administration of bradykinin (500 ng/paw), TNF-α (2.5 pg/paw), IL-1β (0.5 pg/paw), CINC-1 (100 pg/paw) in the subcutaneous tissue of rat hind paw induced mechanical hyperalgesia measured 3 h after its injection. ACEA (1 µg/paw) was administered at the same site 2.5 h after bradykinin (BK), TNF-α, IL-1β, and CINC-1. ACEA (1 µg/paw) significantly reduced the mechanical hyperalgesia induced by bradykinin (Unpaired t-test; P < 0.05) as indicated by the symbol "*" but did not affect the mechanical hyperalgesia induced by TNF-α, IL-1β, CINC-1 (Unpaired t-test; P > 0.05). Carrageenan (100 µg/paw) in subcutaneous tissue of rat hind paw increased concentrations of TNF-α, IL-1β and CINC-1, measured 3 h after its injection. ACEA (0.1 µg/paw) administered at the same site 2.5 h after carrageenan did not affect concentration of TNF-α, IL-1β or CINC-1 (B, C and D, respectively). The symbol "*" means different from control group (One-way ANOVA, Tukey's test; P < 0.05).Sal: Saline. agreement with previous studies demonstrating that the activation of peripheral CB 1 receptor produces an anti-hyperalgesic effect in animal models of inflammatory pain (Amaya et al., 2006; Nackley et al., 2003; Richardson et al., 1998) .
Although it has been demonstrated that CB 1 receptor is expressed on macrophages and keratinocytes (Jean-Gilles et al., 2015; Mai et al., 2015) , the anti-inflammatory effect of its activation in these cells is not clear. CB 1 receptor activation by ACEA in carrageenan-induced inflammation did not change the release of pro-inflammatory cytokines in the peripheral tissue. In fact, our findings showed that CB 1 receptor activation by ACEA administered in peripheral tissue did not alter the hyperalgesia induced by pro-inflammatory cytokines TNFα, IL-1β or CINC-1. Thus, the CB 1 receptor activation on macrophages or keratinocytes does not explain the anti-hyperalgesic effect observed in the present study. Furthermore, to demonstrate that the anti-hyperalgesic effect of ACEA administration in the peripheral tissue involves the neuronal CB 1 receptor activation on the nociceptor, we performed experiments using the intrathecal treatment with antisense ODN against CB 1 receptor that knocked down CB 1 receptor in the nociceptor. Indeed, antisense ODN against CB 1 receptor prevented the antihyperalgesic effect of ACEA on the carrageenan-induced hyperalgesia, confirming the anti-hyperalgesic role of CB 1 receptor expressed on peripheral nociceptor. These findings are supported by a previous study demonstrating that deletion of CB 1 receptors from nociceptors increases mechanical hyperalgesia induced by CFA (Agarwal et al., 2007) .
It is noteworthy that the mechanical hyperalgesia induced by carrageenan is mediated by the release of bradykinin that, in turn, leads to the release of the pro-inflammatory cytokines, TNF-α, IL-1β, and CINC-1. The release of these cytokines results in the local production and release of prostaglandins and sympathetic amines that ultimately induce hyperalgesia by directly sensitizing nociceptors (Ferreira et al., 1993b (Ferreira et al., , 1974 . However, the data of this study demonstrated that, although neuronal CB 1 receptor activation did not prevent the hyperalgesia induced by the pro-inflammatory cytokines TNF-α, IL-1β, and CINC-1, it prevented the hyperalgesia induced by the inflammatory agent carrageenan or the inflammatory mediator bradykinin administered in the peripheral tissue. Interestingly, the hyperalgesia induced by bradykinin, but not by TNF-α, IL-1β or CINC-1 depends on the release of ATP and activation of neuronal P2X 3 receptor (de Oliveira Fusaro et al., 2010) . Moreover, the release of ATP and P2X 3 receptor activation is also crucial to the carrageenan-induced hyperalgesia development (Oliveira et al., 2009) . Therefore, from these data, it is conceivable that the anti-hyperalgesic effect of CB 1 receptor activation involves the inhibition of P2X 3 receptor. Indeed, studies suggest that the antinociceptive effect of cannabinoid receptor activation might be associated with its interaction with purinergic receptors. Local administration of carrageenan in the rat hind paw induced mechanical hyperalgesia 3 h after, which was decreased by ACEA administered 2.5 h after carrageenan. This anti-hyperalgesic effect was reversed by intrathecal administration of antisense ODN. The symbol ''*" means statistically different from other groups (One-way ANOVA, Tukey's test; P < 0.05). (B) The administration of antisense ODN reduced CB 1 receptor expression in DRG. The symbol ''*" means statistically different from mismatch group (Unpaired t-test; P < 0.05). On the right of the graph, a Ponceau S stained membrane showing total protein for each group is presented. For CB 1 expression analysis, the optical density value of the whole lane is considered as the internal control for the respective group. Sal: saline. AS: antisense ODN. MW: molecular weight.
For instance, cannabinoids modulate the ATP-activated currents mediated by P2X 2 and P2X 2/3 receptors in sensory neurons (Krishtal et al., 2006) . In the present study, we showed that local pre-treatment with ACEA reduced the mechanical hyperalgesia induced by the nonselective P2X 3 receptor agonist α,β-meATP in the subcutaneous tissue of rat hind paw. It is noteworthy that α,β-meATP is an agonist of purinergic P2X receptor. However, once P2X 3 receptors are very highly expressed in the DRG compared to other P2X receptors (Dunn et al., 2001; Xiang et al., 1998) , in this study we considered α,β-meATP as a non-selective agonist of P2X 3 receptors.
Finally, this study demonstrated that CB 1 and P2X 3 receptors are co-localized in DRG small-diameter neurons corroborating the findings of Walczak et al. (2009) on the interaction between these two receptors. In addition, CB 1 receptor activation decreases the responsiveness of α,β-meATP-responsive small-diameter neurons in primary DRG culture. These data suggest that CB 1 receptor activation negatively modulates P2X 3 receptor activity (Fig. 5) . Although the molecular mechanism involved in this modulation is not clear, a possible candidate promoting the link between CB 1 and P2X 3 receptors could be cAMP (Krishtal et al., 2006) . Cannabinoid CB 1 receptor is a member of the large family of G-protein-coupled receptor and can have its effects mediated by inhibition of adenylyl cyclase and subsequent reduction of cAMP-dependent protein kinase (PKA) activity. Once P2X receptors contain many phosphorylation sites for PKA, which regulate its function, it is plausible to suggest that the activity of P2X 3 receptor could be modulated by CB 1 receptor through the tuning down of PKA activity. Still, considering that small diameter DRG neurons are known to sense pain and thermal stimuli, especially heat stimuli (Patapoutian et al., 2003) , and P2X 3 receptors on those neurons take part in thermal hyperalgesia (Burnstock, 2009; Shimizu et al., 2005) , experiments evaluating the interaction between CB 1 and P2X 3 receptors, and thermal pain would be interesting. However, since this study is part of systematic studies developed by our research team on P2X 3 receptors and mechanical hyperalgesia (dos Santos et al., 2014; Prado et al., 2013; de Oliveira Fusaro et al., 2010) , only mechanical pain was evaluated.
In conclusion, our data indicate that the activation of CB 1 receptors in the peripheral tissue, expressed on nociceptive afferent fibers, inhibits the inflammatory hyperalgesia by a mechanism involving the reduction of neuronal P2X 3 receptor activity. Clinically, these data Fig. 4 . Activation of cannabinoid CB 1 receptor reduces α,β-meATP-induced hyperalgesia in rat hind paw and decreases the responsiveness of DRG small-diameter neurons to the α,β-meATP. (A) Local administration of α,β-meATP (50 ng/paw) in the subcutaneous tissue of rat hind paw induced mechanical hyperalgesia evaluated 3 h after its injection. ACEA (1 µg/ paw) was administered at the same site 2.5 h after and reduced the α,β-meATP-induced mechanical hyperalgesia. The symbol "*" indicates response significantly lower than that induced by α,β-meATP (Unpaired t-test; P < 0.05). (B) The administration of α,β-meATP (30 µM) induced a rise in intracellular calcium levels in 29.4% cultured DRG small-diameter neurons. In contrast, ACEA (3 µM) reduced 96% the responsiveness of α,β-meATP-responsive DRG small-diameter neurons. The symbol "*" indicates response significantly lower than that induced by α,β-meATP (Unpaired t-test; P < 0.05). Fig. C and D are representative of the response of cell pre-treated with ACEA or with its vehicle to α,β-meATP. (E) Co-staining of CB 1 and P2X 3 receptors in DRG small-diameter neurons (white arrow). DRG sections were staining with the anti-CB 1 receptor (red), anti-P2X 3 receptor (green) and nuclei with DAPI (blue). The merged picture shows co-localization of CB 1 and P2X 3 receptors in DRG small-diameter neurons. (For interpretation of the references to color in this figure legend,the reader is referred to the web version of this article.) suggest that CB 1 receptor can represent an alternative therapeutic target to control inflammatory pain.
